Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study

Table 3 Crude and adjusted associations of myocardial delayed enhancement with DAS28

Characteristic	Model 1		Model 2		Model 3		Model 4		Model 5		Model 6
	β	P	β	P	β	P	β	P	β	P	β	P
Delayed enhancement*	1.32	0.018	1.82	0.002	1.89	0.004	1.78	0.003	1.71	0.005	1.88	0.002
Male gender*			1.36	0.031	1.39	0.036	1.48	0.036	1.47	0.029	1.78	0.042
Age, per year**					-0.01	0.74
RA duration, per year**							0.02	0.64
TNF inhibitor use*									-0.36	0.49
Framingham risk score, per%											-0.07	0.45
R^{2 (†)}	0.31		0.49		0.50		0.50		0.51		0.51

* β coefficients represent the average change in the outcome (DAS28) for those with the characteristic vs. those without.
** β coefficients represent the average change in the outcome (DAS28) per 1 unit increase in the characteristic.
† R² is the percentage of the total variability in the outcome explained by the aggregate of the predictors in the model.

ISSN: 1478-6362